PENK and triple-negative breast carcinoma: In fact, an intermittent low-dose naltrexone treatment in a cell culture model of a highly aggressive, invasive and poorly differentiated triple-negative breast cancer has been shown to promote the production of endogenous OGF, which results in inhibition of DNA synthesis and a 35% reduction in cell numbers [59].